Tuesday, 23 Apr 2019

You are here

HLA-B*5801 Testing Needed in Asians and Blacks with Gout

Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol). (Citation source http://buff.ly/269RMHy)

They found 606 SJS/TEN hospitalizations while receiving ULT. There was an overrepresentation of Asians (27%) and Blacks (26%), and an underrepresentation of Whites (29%) and Hispanics (% too low to report).

These SJS/TEN events were 12 time more frequent in Asians, and 5 times more frequent in Blacks when compared to Whites (reference group).

The HLA-B*5801 allele has been strongly linked with the allopurinol hypersensitivity syndrome and has been found in higher frequency in certain populations, especially Koreans, Japanese, Thai and Han Chinese - and in some Europeans. This study demonstrates the potential use of HLA-B*5801 in U.S. Asians and Blacks.

The authors conclude that the overrepresentation of Asians and Blacks withSJS or TENS while on ULT calls for caution when prescribing allopurinol, and that HLA-B*5801 testing may be more widely applied in the U.S. gout population.

Rheumatologists' Comments

The "headline" here ("HLA-B*5801 Testing Needed in Asians and Blacks with Gout") is NOT what the authors of this study concluded; they concluded "these findings support the use of vigilance in these minorities when considering allopurinol." And, while the relative risks looks concerning, the very low rates of SJS/TEN with allopurinol do not necessarily warrant routine screening every patient of African American or Asian descent. We would need a cost analysis to know whether it makes sense; do we know how much HLA-B*5801 testing costs? Also, this study noted that "the US Japanese population has a low allele frequency of HLA-B*5801 (0.8%)...similar to US Whites as well as the Japanese population of Japan (0.6%) .... we expect a risk level similar to that of Whites' - so, again, the study does not support the headline as stated.
Rob, I concur with your critique of the title. I did reword this title to be provacative and make others think about this paper and issue. Without this and with a conservative title of Allopurinil SJS/TENS Events are Enriched in Certain Populations" would have garnered about 12 readers. Prior to reading this I never gave much consideration of B5801 testing - it seemed reserved largely for Han Chinese and other SE Asian populations as a risk factor. The authors conclusion and call for "vigilance in these minorities when considering alcohol" to me speaks for consideration of wider testing or preferably, the need for studies that look into the predictive value first and then cost analyses second (such tests are not cheap as you suggest!). I think thoughtful comments (like yours) and smart research (TBD) are needed on this issue, if not the challenging title. Thanks!

More Like This

Chronic Kidney Disease Augments Gout Risks

A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.

A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.  

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.